AKT1 and lung carcinoma: Since lidocaine can inhibit the PI3K/Akt pathway in several cancer models, such as liver cancer, lung cancer, and neuroblastoma, this leads to the assumption that it may affect the Hippo pathway through an indirect mechanism, as it can inhibit MST1/2, which reduces the phosphorylation of LATS1/2 and causes more activation of YAP [58].